Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 2
2002 2
2003 2
2004 1
2011 2
2014 1
2015 1
2016 3
2017 3
2018 5
2019 4
2020 11
2021 13
2022 12
2023 11
2024 8
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.
Warrick JI, Hu W, Yamashita H, Walter V, Shuman L, Craig JM, Gellert LL, Castro MAA, Robertson AG, Kuo F, Ostrovnaya I, Sarungbam J, Chen YB, Gopalan A, Sirintrapun SJ, Fine SW, Tickoo SK, Kim K, Thomas J, Karan N, Gao SP, Clinton TN, Lenis AT, Chan TA, Chen Z, Rao M, Hollman TJ, Li Y, Socci ND, Chavan S, Viale A, Mohibullah N, Bochner BH, Pietzak EJ, Teo MY, Iyer G, Rosenberg JE, Bajorin DF, Kaag M, Merrill SB, Joshi M, Adam R, Taylor JA 3rd, Clark PE, Raman JD, Reuter VE, Chen Y, Funt SA, Solit DB, DeGraff DJ, Al-Ahmadie HA. Warrick JI, et al. Among authors: funt sa. Nat Commun. 2022 Nov 2;13(1):6575. doi: 10.1038/s41467-022-34251-3. Nat Commun. 2022. PMID: 36323682 Free PMC article.
Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Hoyos D, Zappasodi R, Schulze I, Sethna Z, de Andrade KC, Bajorin DF, Bandlamudi C, Callahan MK, Funt SA, Hadrup SR, Holm JS, Rosenberg JE, Shah SP, Vázquez-García I, Weigelt B, Wu M, Zamarin D, Campitelli LF, Osborne EJ, Klinger M, Robins HS, Khincha PP, Savage SA, Balachandran VP, Wolchok JD, Hellmann MD, Merghoub T, Levine AJ, Łuksza M, Greenbaum BD. Hoyos D, et al. Among authors: funt sa. Nature. 2022 Jun;606(7912):172-179. doi: 10.1038/s41586-022-04696-z. Epub 2022 May 11. Nature. 2022. PMID: 35545680 Free PMC article.
Ovarian malignancies.
Funt SA, Hricak H. Funt SA, et al. Top Magn Reson Imaging. 2003 Aug;14(4):329-37. doi: 10.1097/00002142-200308000-00005. Top Magn Reson Imaging. 2003. PMID: 14578777 Review.
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ, Sarfaty M, Teo MY, Ratna N, Duzgol C, Funt SA, Lee CH, Aggen DH, Regazzi AM, Chen Z, Lattanzi M, Al-Ahmadie HA, Brannon AR, Shah R, Chu C, Lenis AT, Pietzak E, Bochner BH, Berger MF, Solit DB, Rosenberg JE, Bajorin DF, Iyer G. Guercio BJ, et al. Among authors: funt sa. Clin Cancer Res. 2023 Nov 14;29(22):4586-4595. doi: 10.1158/1078-0432.CCR-23-1283. Clin Cancer Res. 2023. PMID: 37682528 Free PMC article.
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.
Herati RS, Knorr DA, Vella LA, Silva LV, Chilukuri L, Apostolidis SA, Huang AC, Muselman A, Manne S, Kuthuru O, Staupe RP, Adamski SA, Kannan S, Kurupati RK, Ertl HCJ, Wong JL, Bournazos S, McGettigan S, Schuchter LM, Kotecha RR, Funt SA, Voss MH, Motzer RJ, Lee CH, Bajorin DF, Mitchell TC, Ravetch JV, Wherry EJ. Herati RS, et al. Among authors: funt sa. Nat Immunol. 2022 Aug;23(8):1183-1192. doi: 10.1038/s41590-022-01274-3. Epub 2022 Jul 28. Nat Immunol. 2022. PMID: 35902637 Free PMC article.
Extramammary Paget disease. Part II. Evidence-based approach to management.
Shah RR, Shah K, Wilson BN, Leitao MM, Smogorzewski J, Nguyen KA, Crane C, Funt SA, Hosein S, Dafinone M, Rossi A. Shah RR, et al. Among authors: funt sa. J Am Acad Dermatol. 2024 Sep;91(3):421-430. doi: 10.1016/j.jaad.2023.07.1052. Epub 2024 Apr 6. J Am Acad Dermatol. 2024. PMID: 38588817 Review.
Reply to S. Zhang.
Lattanzi M, Funt SA, Rosenberg JE. Lattanzi M, et al. Among authors: funt sa. J Clin Oncol. 2022 Aug 10;40(23):2657-2658. doi: 10.1200/JCO.22.00809. Epub 2022 May 24. J Clin Oncol. 2022. PMID: 35609227 No abstract available.
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
Vanguri RS, Smithy JW, Li Y, Zhuang M, Maher CA, Aleynick N, Peng X, Al-Ahmadie H, Funt SA, Rosenberg JE, Iyer G, Bajorin D, Mathews JC, Nadeem S, Panageas KS, Shen R, Callahan MK, Hollmann TJ. Vanguri RS, et al. Among authors: funt sa. J Pathol. 2023 Nov;261(3):349-360. doi: 10.1002/path.6197. Epub 2023 Sep 5. J Pathol. 2023. PMID: 37667855 Free PMC article.
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.
Holm JS, Funt SA, Borch A, Munk KK, Bjerregaard AM, Reading JL, Maher C, Regazzi A, Wong P, Al-Ahmadie H, Iyer G, Tamhane T, Bentzen AK, Herschend NO, De Wolf S, Snyder A, Merghoub T, Wolchok JD, Nielsen M, Rosenberg JE, Bajorin DF, Hadrup SR. Holm JS, et al. Among authors: funt sa. Nat Commun. 2022 Apr 11;13(1):1935. doi: 10.1038/s41467-022-29342-0. Nat Commun. 2022. PMID: 35410325 Free PMC article. Clinical Trial.
75 results